Introduction
============

Multimorbidity has been defined as the presence of two or more chronic conditions in one individual ( [@ref-6]). The rising prevalence of multimorbidity can be attributed to improvements in healthcare and the ageing population associated with the epidemiologic transition ( [@ref-13]). A 2012 UK study involving over 1 million patients reported that 23.2% had two or more chronic conditions, while this rate increased to 65% when the population considered was restricted to those aged 65--84 years ( [@ref-1]). Patients with multimorbidity are placed at increased risk of experiencing fragmented care due to the disease-centric care model currently dominating medical research, education, and practice ( [@ref-18]). Accordingly, synthesising the relevant evidence existing to date is required to guide future research and practice in the context of multimorbidity.

Adherence refers to the extent to which a person's behaviours correspond with agreed recommendations from their healthcare provider ( [@ref-7]). As well as changes to lifestyle behaviours, patients with chronic diseases are often expected to adhere to complex drug regimens ( [@ref-12]). In the context of multiple conditions, the likelihood of medication non-adherence increases as patients are prescribed more medications ( [@ref-2]), with associated risks to health outcomes ( [@ref-21]). Such non-adherence poses potential problems for both patients and health systems, highlighting a need to further investigate the occurrence of medication non-adherence and associated factors in multimorbidity according to existing evidence.

Despite knowledge of the rising prevalence of multimorbidity, much intervention development to enhance medication adherence and reviews of the adherence literature are centred on single-disease populations ( [@ref-19]). Such a focus is at odds with the rising prevalence of multimorbidity and may lead to an artificial underestimation of the complexity of self-management in chronic disease. One existing systematic review has evaluated medication adherence in older adults with polypharmacy, a phenomenon closely associated with multimorbidity ( [@ref-20]). They cite caregiver burden, impaired hearing, poor cognition and greater number of drugs as predictors of non-adherence in that population ( [@ref-20]). Nevertheless, it has been noted that while relative risk of multimorbidity increases with age, the absolute prevalence of multimorbidity is higher among adults aged under 65 years ( [@ref-1]). Additionally, while multimorbidity and polypharmacy have been branded as "two sides of the same coin" ( [@ref-16]), it has also been noted that the phenomena may be independent of one another depending on the definition and measurement used in individual studies ( [@ref-11]). Therefore, a review of the literature inclusive of all adults with multimorbidity is considered necessary to provide the breadth of understanding required to inform intervention development relevant to the whole population of patients with multimorbidity.

Quantitative studies have reported prevalence rates and predictors of medication non-adherence in adult patients with two or more chronic conditions, however to our knowledge no synthesis of this evidence exists to date. Understanding non-adherence to prescribed medications among patients with multiple chronic conditions will provide insight which goes beyond the single-disease focus currently dominating adherence research. The proposed systematic review aims to identify an evidence base to inform research and practice involving patients with multimorbidity, who comprise a large proportion of the population living with chronic disease.

Research questions
==================

The primary objective of the review is to systematically examine existing evidence relating to prevalence of medication non-adherence and predictors of medication non-adherence among patients with multimorbidity.

The review will specifically address three research questions:

1.  What is the prevalence of medication non-adherence among patients with multimorbidity?

2.  What are the clinical and psychosocial predictors of medication non-adherence among patients with multimorbidity?

3.  Is the method of medication adherence measurement a moderator of non-adherence estimates in multimorbidity?

Methods
=======

Study registration
------------------

The study is prospectively registered in PROSPERO, the International Prospective Register of Systematic Reviews ( [CRD42019133849](https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=133849)).

Study design
------------

The study will be conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) ( [@ref-9]). Each stage of the study selection process will be reported, from title and abstract screening through to selection of full-text articles for inclusion in the review. Reasons for exclusion during full-text review will be reported. A PRISMA flow diagram will be generated to outline each stage of this process. The present systematic review protocol is reported according to PRISMA-P guidelines ( [@ref-10]) (see *Reporting guidelines*; [@ref-5]). Any amendments to the study protocol will be documented here and in the associated PROSPERO document.

Ethics and dissemination
------------------------

As the study protocol is for a systematic review of existing evidence, ethical approval is not required. The results of the systematic review will be reported in a peer-reviewed journal, presented at relevant health research conferences, and included in a PhD thesis.

Systematic reviewing
====================

Types of studies
----------------

Experimental and non-experimental quantitative studies reporting prevalence of medication non-adherence in people with two or more chronic conditions will be included in the review. Observational studies -- including longitudinal and cross-sectional studies -- are anticipated to be the most pertinent study type reviewed. Where intervention studies (randomised and non-randomised controlled trials) report prevalence and/or determinants of medication non-adherence, only baseline data will be extracted and used in the review. The presence of multimorbidity (two or more chronic conditions) must be explicit (i.e. part of study aims and/or inclusion criteria) for studies to be included in the review.

Population
----------

Adults aged 18 years or older with two or more chronic conditions.

Outcome
-------

Prevalence of medication non-adherence measured using any relevant method, e.g. self-report, pharmacy data, physical tests, etc.

Information sources
-------------------

The review will employ the following electronic databases: PsycINFO, PubMed, EMBASE, and CINAHL. Articles considered eligible for inclusion will be available in English and in full-text from January 2009 to April 2019. The search strategy will combine terms relating to adherence and multimorbidity (see *Extended data*; [@ref-5]). The date range is deemed appropriate considering the scope of adherence prevalence studies conducted in people with two or more chronic conditions since [@ref-6] called for "a more uniform methodology" in multimorbidity research, promoting consistency in how multimorbidity is defined within the literature.

Data collection, data extraction, study assessment
==================================================

Study selection
---------------

Studies identified from database searching will be exported to Endnote X8® where duplicated references will be identified and excluded using the 'find duplicates' function, and then screened manually for outstanding duplicates by listing studies in order of title. Remaining studies will be exported to Covidence review management software for screening. Titles and abstracts will be screened by a single reviewer (LF will screen 50% and RLV will screen 50%). To assess agreement between reviewers, 20% of these records will be cross-checked by the other reviewer (LF, RLV). Full-text articles will be independently screened by two members of the review panel (LF, JL). Reference lists of all included studies will be independently searched by two reviewers for additional relevant articles. Where disagreement arises between reviewers at any stage, a third reviewer (GJM and/or AWM depending on subject expertise required) will be consulted.

Data extraction
---------------

Data extraction will be performed by two independent reviewers (LF, JL). A pre-defined data-extraction form will be used (see *Extended data*; [@ref-5]) to extract the following: country of publication, citation, study aims, study design, study setting, chronic conditions studied, sample size, participant age, participant gender, definition of multimorbidity used (if applicable), definition of medication adherence, measure of medication adherence, prevalence of medication non-adherence (or non-adherence score), predictors of medication non-adherence (if reported), authors' conclusions. Where disagreement occurs, a third reviewer (GJM) will be consulted. Where reported data are deemed unclear or insufficient, corresponding authors will be contacted by LF for clarification.

Quality appraisal
-----------------

Study-level quality appraisal will be conducted for all included studies by two reviewers (LF, JL) using criteria for assessing quality and risk of bias in observational studies ( [@ref-15]). Specifically, criteria relate to appropriateness of source population, inclusion/exclusion criteria, measurement methods, methods to deal with design-specific sources of bias, design and/or analytical methods, use of statistics, and declarations of conflict of interest and/or funding sources. While RCT designs may be included in the proposed systematic review, the observational nature of the aforementioned tool is considered appropriate as only baseline observations will be extracted from RCT studies for review. No studies will be excluded on the basis of quality appraisal.

Data synthesis
==============

Narrative data synthesis
------------------------

A narrative synthesis of all reviewed studies will be conducted.

Assessment of heterogeneity
---------------------------

The I ^2^ statistic will assess heterogeneity, using an alpha level of 0.05 for statistical significance. An I ^2^ value between 50% and 75% indicates high heterogeneity between studies ( [@ref-8]).

Quantitative data synthesis
---------------------------

Where data support quantitative synthesis, a meta-analysis will be conducted using the metaprop function in R ( [@ref-14]). Study-specific estimates will be pooled to estimate the prevalence of medication non-adherence. A random effects model will be employed to account for between-study heterogeneity ( [@ref-8]). To account for asymmetry, the Clopper Pearson method will be used to calculate binomial proportion confidence intervals ( [@ref-3]). The effect of each individual study on the overall estimates of non-adherence prevalence will be assessed using sensitivity analyses by serial exclusion.

Analysis of subgroups
---------------------

Where data are sufficient, the following *a priori* moderator analyses will be performed:

1.  For method of medication adherence measurement used (e.g. self-report vs. prescription refill vs. serum assay, etc.).

2.  For definition of multimorbidity used (e.g. 2 or more chronic conditions vs. 3 or more chronic conditions, etc.).

Assessment of reporting biases
------------------------------

Publication bias will be assessed by producing and inspecting a funnel plot ( [@ref-4]) and by conducting an Egger test for statistical significance ( [@ref-17]).

Current study status
====================

The systematic review protocol was finalised in March 2019 and the database search was conducted in April 2019. Full-text screening was completed in October 2019. It is anticipated the review will be completed in January 2020.

Discussion
==========

The review will describe the cumulative evidence relating to medication non-adherence prevalence and relevant predictors among patients with multimorbidity. Understanding non-adherence prevalence and associated factors in this population will reflect the current reality of a rising incidence of complex patients. It is expected the prevalence of medication non-adherence will increase in accordance with the complexity of multimorbidity. A potential limitation relates to the restricted date range for database searching and the use of single-review to screen titles and abstracts. Another potential limitation relates to the heterogeneity associated with the experience of multimorbidity. Accordingly, between-study heterogeneity may not support the conduct of quantitative meta-analysis.

Results of the systematic review will be published in a peer-reviewed journal and disseminated at a range of health research conferences. The systematic review is part of a larger PhD project which aims to identify and understand predictors of non-adherence in multimorbidity in order to guide intervention development to support medication adherence for patients with multimorbidity.

Data availability
=================

Underlying data
---------------

No underlying data are associated with this article.

Extended data
-------------

Open Science Framework: Prevalence and predictors of medication non-adherence among patients with multimorbidity: A systematic review and meta-analysis. <https://doi.org/10.17605/OSF.IO/9Y3RH> ( [@ref-5]).

The following files are available as extended data on Open Science Framework (OSF):

-   Search Strategy PsycINFO.pdf (search strategy to be used)

-   Data Extraction Form.pdf

Reporting guidelines
--------------------

Open Science Framework: PRISMA-P checklist for 'Prevalence and predictors of medication non-adherence among patients with multimorbidity: A systematic review and meta-analysis'. <https://doi.org/10.17605/OSF.IO/9Y3RH> ( [@ref-5]).

Data are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](http://creativecommons.org/publicdomain/zero/1.0/) (CC0 1.0 Public domain dedication).
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Version 1

I have reviewed both the protocol paper and the posting at OSF. I am reviewing the protocol after the authors believe they will have finished the data extraction. 

Overall I do believe this fills a narrow gap in the literature - what is the prevalence of medication non-adherence in all ages of patients with 2 or more chronic diseases. (Not sure if it will include the pediatric literature since not explicitly addressed.) The breadth of the potential diseases that could be included in this review is quite large, as is the type of medication involved. While I concur that previous narrow focus on single disease states or on elderly only has not been adequate, the proposed review seems to somewhat naively view looking at 2 or more diseases as helping us understand non-adherence better. The predictors of non-adherence to be collected do not include type of medication (oral (qd, bid ,tid, etc.), injectable (IM, subcu; daily, weekly, monthly etc.; prn or scheduled; medication types)). This could be crucial to better understanding non-adherence. Already existent literature has noted frequency of medication dosage and number of drugs being prescribed as predictors of adherence. (There is already literature on polypills as a way to improve adherence in those who are prescribed multiple drugs for cardiovascular disease prevention). Other predictors are also out there - cost of medications and other barriers to obtaining them. 

The authors have faithfully followed the PRISMA-P recommendations for reporting, their search strategy seems appropriate. One modest concern is that they will not exclude any studies on the basis of quality. I would argue that if the study is a case series and therefore cannot really assess prevalence in the underlying population, it should be excluded. I hope this review will lead the authors to looking next at interventions to improve adherence in this population as I predict the non-adherence rates will be relatively high.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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Version 1

This is a very well written protocol of a systematic review that aims to identify the prevalence and predictors of non-adherence in adult patients with two or more chronic conditions (multi-morbidity). It recognises that the number of patients with multi-morbidity (commonly prescribed multiple medications) is rising, yet the focus of much adherence research is still on single diseases or individual medications. The findings from this review will help to address an important gap in the current adherence literature. There is a clear rationale provided for conducting this systematic review. The methods detailed in the protocol are clearly described, appropriate and in line with current guidelines for conducting and reporting systematic reviews and the PRISMA-P checklist has been completed.

I only have a few minor comments/suggestions, to improve the clarity for readers: It would be helpful to provide a definition for chronic conditions that will be adopted in the systematic review (e.g. The WHO defines them as: \"health problems that require ongoing management over a period of years or decades\").Examples of 'Clinical and psychosocial predictors of medication non-adherence' would be helpful for readers unfamiliar with these terms.Under 'Types of studies', it is currently unclear if studies including patients aged under 18 years will be excluded or if studies will be included if the mean age of study participants is 18 years or over? The authors mention that "Quantitative studies have reported prevalence rates and predictors of medication non-adherence in adult patients with two or more chronic conditions..." but no references have been provided here.  

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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